Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans

Journal of Diabetes & Metabolic Disorders

Udeme Nelson Essien¹  Sonia Chukwuma²  Kate Chinedum Eleazu¹  Chinedum Ogbonnaya Eleazu² 

[1] Department of Biochemistry, Michael Okpara University of Agriculture, Umudike, Umuahia, Abia State, Nigeria;Department of Biochemistry, National Root Crops Research Institute, Umudike, Umuahia, Abia State, Nigeria

关键词: Cell death;    Humans;    Diabetes;    Animals;    Streptozotocin;   

Others  :  806632
DOI  :  10.1186/2251-6581-12-60

 received in 2013-09-16, accepted in 2013-11-05,  发布年份 2013

【 摘 要 】

Streptozotocin (STZ) (2-deoxy-2-({[methyl(nitroso)amino]carbonyl}amino)-β-D-glucopyranose) is a naturally occurring diabetogenic compound, produced by the soil bacterium streptomyces achromogenes, that exhibits broad spectrum of antibacterial properties. Streptozotocin functions as a DNA synthesis inhibitor in both bacterial and mammalian cells. In mammalian cells, the actual mechanism and metabolic targets of STZ toxicity that results in cell death is not known. This review identifies four key areas that explain the mechanism of the cytotoxicity of STZ in mammalian cell lines, investigates the practical aspects of using STZ in experimental animals and the potential risks of its exposure to human health.

【 授权许可】

   
2013 Eleazu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Dolan ME: Inhibition of DNA repair as a means of increasing the antitumor activity of DNA active agents. Adv Drug Del Rev 1997, 26:105-118.
• [2]Vivek KS: Streptozotocin: an experimental tool in diabetes and alzheimer’s disease (A- Review). Int J Pharma Res Dev 2010, 2(1):1-7.
• [3]Lenzen S: Alloxan and streptozotocin diabetes. Diabetologia 2007, 51:216-226.
• [4]Rakieten L, Rakieten ML, Nadkarni MV: Studies on the diabetogenic action of Streptozotocin (NSC-37917). Cancer Chem Rep 1963, 29:91-98.
• [5]Rerup CC: Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol Rev 1970, 22:485-518.
• [6]Bolzan AD, Bianchi MS: Genotoxicity of Streptozotocin. Mutat Res 2002, 512:121-134.
• [7]Reusser F: Mode of Action of Streptozotocin. J of Bact 1971, 105:580-588.
• [8]Junod A, Lambert AE, Orci L, Pictet R, Gonet AE, REnold AE: Studies of the diabetogenic action of streptozotocin. Proc Soc Exp Biol Med 1967, 126:201-205.
• [9]Ventura-Sobrevilla J, Boone-Villa VD, Aguilar CN, Román-Ramos R, Vega-Ávila E, Campos-Sepúlveda E, Alarcón-Aguilar F: Effect of Varying Dose and Administration of Streptozotocin on Blood Sugar in Male CD1 Mice. Proc West Pharmacol Soc 2011, 54:5-9.
• [10]Povoski SP, McCullough PJ, Zhou H, Bell RH: Induction of diabetes mellitus in Syrian golden hamsters using stored equilibrium solutions of Streptozotocin. Lab Animal Sci 1993, 43:310-314.
• [11]Sharma S, et al.: Experimental Models of Diabetes. Int J Res Ayurveda and Pharm 2010, 1(2):292-301.
• [12]Joo HL, Si HY, Jung MOH, Myung GL: Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus. J Pharm Pharmacol 2010, 62:1-23.
• [13]Elsner M, Guldbakke B, Tiedge M, Munday R, Lenzen S: Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin. Diabetolgia 2007, 43:1528-1533.
• [14]Eleazu CO, Iroaganachi M, Eleazu KC: Ameliorative Potentials of Cocoyam (Colocasia esculenta L.) and Unripe Plantain (Musa paradisiaca L.) on the Relative Tissue Weights of Streptozotocin-Induced Diabetic Rats. J Diabetes Res 2013a 2013, 2013(160964):8. doi:10.1155/2013/1609640
• [15]Valentovic MA, Alejandro N, Betts CA, Brown PI, Ramos K: Streptozotocin (STZ) diabetes enhances benzo(alpha)pyrene induced renal injury in Sprague Dawley rats. Toxicol Lett 2006, 164:214-220.
• [16]Ferrer J, Benito C, Gomis R: Pancreatic islet GLUT 2 glucose transporter mRNA and protein expression in humans with and without NIDDM. Diabetes 1995, 44:1369-1374.
• [17]Koehn J, et al.: Multiple drug resistance associated with function of ABC-transporters in diabetes mellitus: molecular mechanism and clinical relevance. Infect Disord Drug Targets 2008, 8:109-118.
• [18]Xie W, et al.: A new tactic to treat postprandial hyperlipidemia in diabetic rats with gastroparesis by improving gastrointestinal transit. Eur J Pharmacol 2005, 510:113-120.
• [19]Loannides C: Chapter 12. Expression of cytochrome P450 protein in disease. In Cytochrome P450. Metabolic and toxicological aspects. Boca Raton, New York, London, Tokyo: CRC Press; 1996:301-327.
• [20]Ryan JP, Irwin JA: Practical studies on urine demonstrating principles of clinical and veterinary significance. Biochem Mol Biol Educ 2002, 30:98-100.
• [21]Tesch GH, Allen TJ: Nephrology. 2007, 12:261-266.
• [22]Murata M, Takahashi A, Saito L: Takanishi, S: Site-specific DNA methylation and apoptosis: induction by diabetogenic streptozotocin. Biochem Pharmacol 1999, 57:881-887.
• [23]Piepper AA, Verma A, Zhang J, Snyder SH: Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci 1999, 20:171-181.
• [24]Stauffacher W, Burr I, Gutzeit I, Beaven D, Veleminsky J, Renold AE: Streptozotocin diabetes: time course of irreversible β-cell damage; further observations on prevention by nicotinamide. Proc Soc Exp Biol Med 1970, 133:194-200.
• [25]Som NS, Praveen V, Shoba S, Radhey S, Kumria MML, Ranganathan S, Sridharan K: Effect of an anti-diabetic extract of Catharanthus roseus on enzymic activities in streptozotocin induced diabetic rats. J Ethnopharmacol 2001, 76:269-277.
• [26]Friederich M, Hansell P, Palm F: Diabetes, oxidative stress, nitric oxide and mitochondria function. Curr Diabetes Rev 2009, 5:120-144.
• [27]Spinas GA: The dual role of nitric oxide in islets β-cells. News Physiol Sci 1999, 14:49-54.
• [28]Atalay M, Laaksonen DE: Diabetes, oxidative stress and physical exercise. J Sports Sci & Med 2002, 1:1-14.
• [29]West IC: Radicals and oxidative stress in diabetes. Diabet Med 2000, 7:171-180.
• [30]Hunt JV, Smith CC, Wolff SP: Auto-oxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 1990, 39:1420-1424.
• [31]Matsuoka T, Kajimoto Y, Watada H, Kaneto H, Kishimoto M, Umayahara Y, Fujitani Y, Kamada T, Kawamori R, Yamasaki Y: Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J Clin Invest 1998, 99:144-150.
• [32]Gul M, Laaksonen DE, Atalay M, Vider L, Hannien O: Effects of endurance training on tissue glutathione homoestasis and lipid peroxidation in streptozotocin-induced diabetic rats. Scand J Med Sci Sports 2002, 12:163-170.
• [33]Henriksen EJ: Invited review: Effects of acute exercise and exercise training on insulin resistance. J Appl Physiol 2002, 93:788-796.
• [34]Pushparaj P, Tan CH, Tan BKH: Effects of Averrhoa bilimbi leaf extract on blood glucose and lipids in streptozotocin-diabetic rats. J Ethnopharmacol 2000, 72:69-76.
• [35]Vergani L, Floreani M, Russell A, Ceccon M, Napoli E, Cabrelle A, Valente L, Bragantini F, Leger B, Dabbeni-Sala F: Antioxidant defences and homeostasis of reactive oxygen species in different human mitochondrial DNA-depleted cell lines. Eur J Biochem 2004, 271:3646-3656.
• [36]Konrad RJ, Mikolaenko I, Tolar JF, Liu K, Kudlow JE: The potential mechanism of the diabetogenic action of streptozotocin: inhibition of pancreatic beta-cell O-GlcNAc-selective N-acetyl-beta-D-glucosaminidase. Biochem J 2001, 356:31-41.
• [37]Krentz AJ: Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diab Obes Metab 2003, 5:S19-S21.
• [38]Haider R, Annie J: Streptozotocin-Induced Cytotoxicity, Oxidative Stress and Mitochondrial Dysfunction in Human Hepatoma HepG2 Cells. Int J Mol Sci 2012, 13:5751-5767. doi: 10.3390/ijms13055751
• [39]Saini KS, Thompson C, Winterford CM, Walker NI, Cameron DP: Streptozotocin at low doses induces apoptosis and at high doses causes necrosis in a murine pancreatic β-cells line, INS-1. Biochem Mol Biol Int 1996, 39:1229-1236.
• [40]Harel A, Bloch O, Vardi P, Bloch K: Sensitivity of HaCat keratinocytes to diabetogenic toxins. Biochem Pharmacol 2002, 63:171-178.
• [41]ADA: American Diabetes Association. Diabetes Care 2002, 32:S62-S67.
• [42]Boroujeni NB, Hashemi SM, Khaki Z, Soleimani M: Tissue Cell. 2011, 43:75-82.
• [43]Arias-Díaz J, Balibrea J: Nutr Hosp. 2007, 22:160-168.
• [44]Etuk EU, Muhammed BJ: Evidence based analysis of chemical method of induction of diabetes mellitus in experimental animals. Asian J Exp Biol Sci 2010, 1(2):331-336.
• [45]Gajdošík A, Gajdošíkova A, Stefek M, Navarova J, Hozová R: Streptozotocin-Induced Experimental Diabetes In Male Wistar Rats. Gen Physiol Biophys 1999, 18(Focus Issue):54-62.
• [46]Ar'Rajab A, Ahrén B: Long-term diabetogenic effect of streptozotocin in rats. Pancreas 1993, 8:50-57.
• [47]Kennedy JK, Zochodne DW: The regenerative deficit of peripheral nerves in experimental diabetes. Its extent, timing, possible mechanism. Brain 2000, 123(10):2118-2212.
• [48]Pharmaceuticals S: Material Safety Data Sheet. Sicor Pharmaceuticals Inc: Irvine CA; 2003.
• [49]Adeghate E, Ponery AS: GABA in the endocrine pancreas: cellular localization and function in normal and diabetic rats. Tissue Cell 2002, 34:1.6.
• [50]Arindkar S: Mahesh kumar MJ, Juyal RC, Majumdar SS, Perumal N: The Effect of Fasting on Haematology Serum Biochemistry Parameters on STZ Induced CD1 Mice and Diabetic db/db Mice. J Drug Metab Toxicol 2012, 3:137. doi: 10.4172/2157-7609.1000137
• [51]Suresh BP, Srmivasan K: Influence of dietary capsaicin and onion on the metabolic abnormalities associated with streptozotocin induced diabetes mellitus. Mol Cell Biochem 1997, 175:49-57.
• [52]Kripa K, Vijayalakshmi NR, Helen A: Methanolic Extract of Costus Igneus (N.E.Br.) Alleviates Dyslipidemia In Diabetic Rats Asian Journal of Pharmaceutical and. Clin Res 2011, 4:1-4.
• [53]Srinivasan K, Patole PS, Kaul CL, Ramarao P: Reversal of glucose intolerance by pioglitazone in high-fat diet fed rats. Methods Find Exp Clin Pharmacol 2004, 26:327-333.
• [54]Calcutt NA, Li L, Yaksh TL, Malmberg AB: Different effects of two aldose reductase inhibitors on nociception and prostaglandin E. Eur J Pharmacol 1995, 285:189-197.
• [55]Dyck PJ, Zimmerman BR, Vilen TH, Minnerath SR, Karnes JL, Yao JK, et al.: Nerve glucose, fructose, sorbitol, myoinositol, and fiber degeneration and regeneration in diabetic neuropathy. N Engl J Med 1988, 319:542-548.
• [56]Courteix C, Eschalier A, Lavarenne J: Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 1993, 53:81-88.
• [57]Malcangio M, Tomlinson DR: A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats. Pain 1998, 76:151-157.
• [58]Aley KO, Levine JD: Rapid onset pain induced by intravenous streptozotocin in the rat. J Pain 2001, 2:146-150.
• [59]Sasaki T, Yasuda H, Maeda K, Kikkawa R: Hyperalgesia and decreased neuronal nitric oxide synthase in diabetic rats. Neuroreport 1998, 9:243-247.
• [60]Cunha JM, Funez MI, Cunha FQ, Parada CA, Ferreira SH: Streptozotocin-induced mechanical hypernociception is not dependent on hyperglycemia. Braz J Med Biol Res 2009, 42:197-206.
• [61]Robbiano L, Mereto E, Corbu C, Brambilla G: DNA damage induced by seven N-nitroso compounds in primary cultures of human and rat kidney cells. Mutat Res 1996, 368:41-47.
• [62]Eleazu CO, Eleazu KC: Ameliorating Potentials of 3 Medicinal Plants on Relative Pancreatic Weights in Streptozotocin Induced Diabetic Rats. J Diabetes Metab 2013, 4:264. doi: 10.4172/2155-6156.1000264
• [63]Eleazu CO, Iroaganachi M, Okafor PN, Ijeh II, Eleazu KC: Ameliorative Potentials of Ginger (Z. officinale Roscoe) on Relative Organ Weights in Streptozotocin induced Diabetic Rats. Int J Biomed Sci 2013, 9(2):82-90.
• [64]IARC: Some N-Nitroso Compounds: IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans. Lyon, France: International Agency for Research on Cancer; 1978:17-365.